Ligand Pharmaceuticals (LGND) stock jumps premarket as BofA starts its coverage with a Buy rating and a $244 target, citing ...
Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc LGND, citing the distinctive ...
The fair value estimate for Ligand Pharmaceuticals has been nudged higher, moving from US$243.44 to US$244.56 in the latest analyst update. That shift is closely tied to refreshed views on QTORIN and ...
Investor's Business Daily on MSN
IBD stock of the day: Ligand Pharma, biotech's royalty arm, breaks out
Ligand Pharmaceuticals is Tuesday's IBD Stock Of The Day. The biotech stock has blown past several buy points on its way to a new breakout.
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company’s royalty-focused business model and diversified ...
As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare ...
This is my tenth Ligand (LGND) article, following my most recent 06/2025 "Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward". In Powers Forward, I rated Ligand as a "Buy". It has since ...
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results